NCT00214981已完成3 期
A 1-Year, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Continued Efficacy of Modafinil (Film-coated Tablet Formulation) in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (Followed by an Open-Ended Extension Period)
Cephalon112 个研究点 分布在 1 个国家开始时间: 2003年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 112
- 主要终点
- Evaluate the safety of treatment with the modafinil film coated tablet.
研究概览
简要总结
Primary objective of this study is to evaluate the safety of treatment with modafinil film-coated tablet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are included in the study if they participated in a previous qualifying study with modafinil and, in the opinion of the investigator, will continue to benefit from treatment with modafinil. In addition, the following criteria must be met:
- •a boy or girl 6 to 17 years of age, inclusive, and English-speaking
- •weight and height between the 5th and 95th percentile on the National Center for Health Statistics (NCHS) growth chart for age, height, and weight
- •if more than 6 months since last dose of study drug, meets the full DSM-IV crieria for ADHD (combined typd, predominantly inattentive type, or predominantly hyperactive - impulsive type) at screening, as manifested by a psychiatric/clinical evaluation and confirmed by a structured diagnostic interview, namely, the Diagnostic Interview Schedule for Children, Fourth Edition (DISC-IV).
- •are in good health (except for a diagnosis of ADHD) as determined by medical and psychiatric history, physical examination, ECG, serum chemistry, hematology, urinalysis
- •girls of child bearing potential (Tanner scale >3) OR all girls 8 years of age and older have a negative urine pregnancy test at screening, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). (NOTE: For conducting pregnancy tests, the investigator has the option of determining the sexual maturity all girls 8 years of age and older.) Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, and injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
- •have a parent or legal guardian who is willing to participate in the study.
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •a history or current diagnosis of pervasive developmental disorder, schizophrenia, or other psychotic disorders, or a clinical assessment of current suicide risk
- •any current psychiatric comorbidity, including but not limited to depression or other mood disorder, anxiety disorder, or pervasive mental disorder, that requires pharmacotherapy
- •a clinically significant drug sensitivity to stimulants such as amphetamine, dextroamphetamine, methylphenidate, pemoline
- •failure to respond to 2 or more adequate courses (dose or duration) of ADHD therapy
- •use of any other prescription medications for ADHD (e.g., amphetamine, dextroamphetamine, methylphenidate, pemoline, atomoxetine) after the screening visit
- •use of any MAO inhibitors or SSRIs within 2 weeks of the baseline visit
- •hypertension, defined as follows (SBP = systolic blood pressure and DBP = diastolic blood pressure):
- •ages 6-9 years SBP > 122mmHg or DBP>78mmHg
- •ages 10-12 years SBP > 126mmHg or DBP>82mmHg
- •ages 13-17 years SBP > 136mmHg or DBP>86mmHg
- •hypotension, defined as sitting systolic blood pressure (taken after resting for 5 minutes) of less than 50mmHg for children under 12 years of age or less than 80mmHg for children 12 and older
- •a sitting pulse outside the range of 60 through 115 bpm after resting for 5 minutes
结局指标
主要结局
Evaluate the safety of treatment with the modafinil film coated tablet.
次要结局
未报告次要终点
研究者
研究点 (112)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate CancerCastration-resistant Prostate CancerCRPCNCT02361086Innocrin Pharmaceutical21
进行中（未招募）
1 期
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With VitiligoVitiligoNCT06625177Teva Branded Pharmaceutical Products R&D LLC66
终止
1 期
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell DiseaseSickle Cell DiseaseNCT03132324Incyte Corporation12
已完成
1 期
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.Paroxysmal Nocturnal HemoglobinuriaNCT02588833Apellis Pharmaceuticals, Inc.23
进行中（未招募）
1 期
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasNCT06226571Syndax Pharmaceuticals96